Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 10/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | PGK1 | P00558 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567266 | 0.83 | GLP1R (0.41) | GPR6CYP2D6GLP1RPGK1PDE10A | |
| SCHEMBL15565354 | 0.80 | GLP1R (0.41) | GPR6GLP1RPGK1PDE10A | |
| SCHEMBL16818337 | 0.79 | ALDH1A1 (0.42) | GPR6CYP2D6PGK1 | |
| SCHEMBL15566210 | 0.77 | GPR6 (0.50) | GPR6CYP2D6PGK1 | |
| SCHEMBL16818335 | 0.77 | PGK1 (0.40) | GPR6CYP2D6PGK1 | |
| SCHEMBL17009593 | 0.74 | GPR6 (0.48) | GPR6CYP2D6 | |
| SCHEMBL16818331 | 0.73 | LATS1 (0.48) | GPR6GLP1R | |
| SCHEMBL17009572 | 0.73 | GPR6 (0.48) | GPR6CYP2D6PGK1 | |
| SCHEMBL17009574 | 0.73 | GPR6 (0.48) | GPR6CYP2D6PGK1 | |
| SCHEMBL12965817 | 0.71 | CYP1A2 (0.46) | GPR6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105230-B1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | Taketa Pharmaceutical Company Limited (JP) | 2019-01-15 | — | — | US | disclosed |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-3105230-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123505-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR6 1/4885CYP2D6 153/4885GLP1R 100/4885 |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR6 1/4885CYP2D6 153/4885GLP1R 100/4885 |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR6 1/4885CYP2D6 161/4885GLP1R 113/4885 |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR6 1/4885CYP2D6 161/4885GLP1R 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.